AbbVie is trading 3% down at $248.68 after healthcare stocks came under pressure on September 8, 2026; the XLV sector ETF fell 2.19% during regular trading.
- The decline appears primarily sector-driven, not tied to a fresh AbbVie-specific negative announcement.
- Recent Apogee acquisition developments and financing needs remain relevant investor considerations.
- BofA Securities raised its price target to $282 and maintained a Buy rating, providing no clear explanation for today’s drop.